FY2025 EPS Estimates for Septerna Decreased by HC Wainwright

Septerna, Inc. (NASDAQ:SEPN) – Stock analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Septerna in a research report issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.99 per share for the year, down from their previous forecast of $1.01. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $22.50 million.

A number of other equities research analysts also recently weighed in on SEPN. Wall Street Zen downgraded shares of Septerna from a “hold” rating to a “sell” rating in a research note on Saturday. Cantor Fitzgerald increased their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Finally, Wells Fargo & Company raised their target price on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 16th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.75.

Septerna Stock Down 5.7%

Septerna stock opened at $10.93 on Tuesday. The stock has a market cap of $487.26 million and a PE ratio of -1.08. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99. The business’s 50-day moving average price is $11.57 and its two-hundred day moving average price is $9.08.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new position in Septerna in the 4th quarter valued at approximately $160,205,000. Samsara BioCapital LLC acquired a new stake in Septerna in the fourth quarter valued at $63,399,000. Driehaus Capital Management LLC acquired a new stake in Septerna in the fourth quarter valued at $59,301,000. BVF Inc. IL bought a new position in Septerna during the 4th quarter worth $56,151,000. Finally, Deep Track Capital LP acquired a new position in Septerna during the 4th quarter worth about $43,806,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.